Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DMACNASDAQ:EVOKNASDAQ:MBRXNASDAQ:ONTXNASDAQ:VCNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$2.49-4.2%$2.85$1.50▼$4.75$98.69M1.6952,729 shs17,421 shsEVOKEvoke Pharma$0.48-12.8%$0.62$0.42▼$2.42$4.65M0.2224,321 shs20,940 shsMBRXMoleculin Biotech$4.54+6.1%$7.07$4.28▼$15.75$9.53M1.9583,774 shs49,637 shsONTXOnconova Therapeutics$0.82$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsVCNXVaccinex$4.80-0.8%$8.11$4.43▼$100.80$5.96M0.7410,574 shs11,069 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics-4.23%-1.97%-11.70%-11.70%+44.77%EVOKEvoke Pharma-12.79%-11.35%-21.38%-37.82%-77.20%MBRXMoleculin Biotech+6.07%-5.02%-42.22%-44.66%-62.17%ONTXOnconova Therapeutics0.00%0.00%+20.64%+44.71%+39.18%VCNXVaccinex-0.83%-29.41%-42.03%-37.66%-95.03%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDMACDiaMedica Therapeutics0.9673 of 5 stars3.53.00.00.01.40.00.0EVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech2.277 of 5 stars3.53.00.00.02.90.01.3ONTXOnconova Therapeutics0.7051 of 5 stars3.53.00.00.00.00.00.0VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics3.00Buy$7.00181.12% UpsideEVOKEvoke PharmaN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$35.00670.93% UpsideONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideVCNXVaccinexN/AN/AN/AN/ACurrent Analyst RatingsLatest ONTX, MBRX, EVOK, VCNX, and DMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AEVOKEvoke Pharma$5.18M0.78N/AN/A($0.77) per share-0.62MBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00VCNXVaccinex$570K10.36N/AN/A($2.59) per share-1.85Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)EVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)MBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)VCNXVaccinex-$20.25M-$100.86N/A∞N/AN/A-2,667.31%-571.70%5/20/2024 (Estimated)Latest ONTX, MBRX, EVOK, VCNX, and DMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A 3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A19.2719.27EVOKEvoke PharmaN/A2.252.09MBRXMoleculin BiotechN/A3.863.86ONTXOnconova TherapeuticsN/A2.792.79VCNXVaccinexN/A0.570.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%EVOKEvoke PharmaN/AMBRXMoleculin Biotech15.52%ONTXOnconova Therapeutics7.95%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics7.20%EVOKEvoke Pharma11.78%MBRXMoleculin Biotech6.70%ONTXOnconova Therapeutics3.30%VCNXVaccinex51.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableEVOKEvoke Pharma48.48 million7.48 millionNot OptionableMBRXMoleculin Biotech152.23 million2.08 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableVCNXVaccinex381.23 million598,000OptionableONTX, MBRX, EVOK, VCNX, and DMAC HeadlinesSourceHeadlineVaccinex faces Nasdaq compliance challengeinvesting.com - April 14 at 7:54 AMVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023investorplace.com - April 2 at 3:02 PMVaccinex Reports 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 2 at 8:30 AMVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 27 at 8:30 AMVaccinex CFO Scott Royer to retire, Jill Sanchez steps ininvesting.com - March 6 at 7:15 PMVaccinex Inc VCNXmorningstar.com - March 2 at 3:46 PMVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technologyfinanznachrichten.de - February 21 at 9:42 AMVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platformmarkets.businessinsider.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyfinance.yahoo.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyglobenewswire.com - February 21 at 8:00 AMVaccinex Announces 1-For-14 Reverse Stock Splitmarkets.businessinsider.com - February 15 at 4:28 PMWhy Vaccinex (VCNX) Stock Is Trading Lowermsn.com - February 15 at 4:28 PMVaccinex, Inc. Announces Reverse Stock Splitglobenewswire.com - February 15 at 8:00 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Incfinance.yahoo.com - February 12 at 2:49 PMVaccinex Inc Secures $3.7M in Private Placement Dealmsn.com - February 8 at 10:26 AMWhy Vaccinex (VCNX) Stock Is Popping Offmsn.com - February 7 at 2:45 PMVaccinex Announces Pricing of $3.7 Million PIPE Financingmarkets.businessinsider.com - February 7 at 9:45 AMA phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.ascopubs.org - January 30 at 7:55 PMNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rulefinance.yahoo.com - December 4 at 8:50 AMVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 9:59 AMVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meetingfinance.yahoo.com - October 31 at 11:18 AMVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseasesfinance.yahoo.com - October 26 at 9:40 AMUnderstanding the Risks of Investing in Vaccinex Inc (VCNX)knoxdaily.com - October 17 at 9:03 PMVaccinex Inc [NASDAQ: VCNX] Sees Decrease in Stock Valueknoxdaily.com - October 6 at 7:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.